Advertisement

 

 

COMPARING 2- AND 3-DOSE 9-VALENT HPV VACCINE SCHEDULES IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS.

Author Information (click to view)

Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M,


Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M, (click to view)

Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

The Journal of infectious diseases 2016 5 27() pii

Abstract

A recent clinical trial using the 9-valent HPV vaccine has shown that antibody responses after 2 doses are non-inferior to 3 doses, suggesting that 2 and 3 doses may have comparable vaccine efficacy. We used an individual-based transmission-dynamic model to compare the population-level effectiveness and cost-effectiveness of 2- and 3-dose schedules of 9-valent HPV vaccine in the United States. Our model predicts that if 2 doses of 9-valent vaccine protect for ≥20 years: 1) the additional benefits of a 3-dose schedule are small compared to 2-dose schedules, and 2) 2-dose schedules are likely much more cost-efficient than 3-dose schedules.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × 2 =

[ HIDE/SHOW ]